Dabrafenib’s medical insurance reimbursement scope

Dabrafenib is an orally administered drug that belongs to a class of drugs called BRAF inhibitors. It is mainly used to treat certain types of cancer, especially those with mutations in the BRAF gene, such as malignant melanoma (melanoma) and non-small cell lung cancer.

Domestic medical insurance reimbursement is limited only to: 1. BRAF V600 Mutation-positive unresectable or metastatic melanoma: combined with trametinib is suitable for the treatment of BRAF V600 Mutation-positive unresectable or metastatic melanoma patients;

2. Postoperative adjuvant treatment of BRAF V600 mutation-positive melanoma: combined with trametinib is suitable for adjuvant treatment of patients with BRAF V600 mutation-positive III melanoma after complete resection;

3. Metastatic non-small cell lung cancer with positive BRAF V600 mutation: combined with trametinib is suitable for the treatment of patients with metastatic non-small cell lung cancer with positive BRAF V600 mutation.

Dabrafenib treats cancer by inhibiting the activity ofBRAF protein. As a BRAFkinase inhibitor, it binds to the activation site of BRAF protein and blocks the phosphorylation activity of BRAF protein, thereby inhibiting the activation of downstream signaling pathways.

Through this mechanism of action, dabrafenib can block the abnormal proliferation of cancer cells, promote tumor cell apoptosis, and inhibit the process of tumor angiogenesis, thereby effectively inhibiting the development of specific types of cancer.

Although dabrafenib has made remarkable achievements in treating cancer, its use may also be accompanied by a series of side effects and drug resistance problems. Therefore, before using dabrafenib, patients should receive guidance from their physician and understand the possible risks and benefits of the drug.

Dabrafenib is now on the market in China and has been included in medical insurance. Patients can purchase it directly in China. However, its price is relatively high, about 10,000 yuan. Please consult the local hospital pharmacy for specific prices. In comparison, the price of foreign generic drugs of dabrafenib is more affordable, especially the price of generic drugs in Laos, which is only about two to three thousand yuan, which is far lower than the domestic price. However, it is worth noting that there is no significant difference in drug ingredients between these foreign generic drugs and domestic original drugs. Therefore, patients can flexibly choose the source of drugs based on their actual situation and financial ability.